Anchor Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Anchor Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,700	Closed	-$400K	–	297
2016 Q3	$400K	Sell	8,700 -11,610	-57%	-$606K	0.01%	225
2016 Q2	$1.02M	Sell	20,310 -14,753	-42%	-$785K	0.03%	167
2016 Q1	$1.88M	Sell	35,063 -4,852	-12%	-$285K	0.05%	138
2015 Q4	$2.62M	Sell	39,915 -846	-2%	-$52.3K	0.07%	137
2015 Q3	$2.3M	Hold	40,761	–	–	0.06%	136
2015 Q2	$2.41M	Sell	40,761 -762	-2%	-$47K	0.05%	141
2015 Q1	$2.59M	Buy	41,523 +2,290	+6%	+$133K	0.06%	143
2014 Q4	$2.26M	Buy	39,233 +14,774	+60%	+$823K	0.05%	153
2014 Q3	$1.31M	Sell	24,459 -7,981	-25%	-$423K	0.03%	181
2014 Q2	$1.7M	Buy	32,440 +15,358	+90%	+$785K	0.03%	164
2014 Q1	$903K	Sell	17,082 -642	-4%	-$29.7K	0.02%	201
2013 Q4	$710K	Sell	17,724 -3,006	-15%	-$118K	0.01%	219
2013 Q3	$783K	Buy	20,730 +6	+0%	+$234	0.02%	193
2013 Q2	$812K	Buy	+20,724	New	+$807K	0.02%	190

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Anchor Capital Advisors's TEVA Position: Q4 2016 in Review

Anchor Capital Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 8,700 shares — an estimated $400K sold.

Anchor Capital Advisors first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $2.62M in Q4 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Anchor Capital Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Anchor Capital Advisors sold 8,700 Teva Pharmaceuticals shares in Q4 2016, an estimated $400K.
Anchor Capital Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Anchor Capital Advisors's Teva Pharmaceuticals position peaked at $2.62M in Q4 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Anchor Capital Advisors's 13F filing for Q4 2016, filed 8 Feb 2017.